Trial reportBMC medicine2026
Impact of diagnosis to ablation time on clinical outcomes in patients with atrial fibrillation: post hoc analysis of the CABANA trial.
Trial report in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00911508 (Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCurrent evidence is limited concerning the temporal impact of atrial fibrillation (AF) ablation timings on post-ablation outcomes.
methodsPatients who experienced ablation in the CABANA trial were enrolled in our analysis. Diagnosis to ablation time (DAT) was calculated from the date when the initial AF episode was documented. The primary endpoint was a composite of death, disabling stroke, serious bleeding or cardiac arrest. Secondary end points included AF recurrence, all-cause mortality, and all-cause mortality or cardiovascular hospitalisation. Associations between DAT and post-ablation outcomes were evaluated by restricted cubic spline (RCS) curves based on Cox models.
resultsOut of 1145 patients (median age 67.0 years, interquartile range (IQR) 61.0-72.0; 36.7% female) included, 538 (47.0%) underwent early ablation (DAT ≤ 1 year), including 242 (45.0%) who received very early ablation (DAT ≤ 90 days). The overall median DAT was 423 days (IQR 118-1473). The L-shaped association was observed between DAT and the primary outcome (P for non-linear = 0.034). The lowest point was located at a DAT of approximately 1 to 3 years. For AF recurrences, the RCS curve rose progressively with increasing DAT (P for non-linear = 0.062), showing a reduced risk when DAT was less than 1 year. Effects of early ablation on the primary outcome favoured patients with initial AAD use (HR 0.86, 95% confidence interval (CI) 0.43-1.73 vs. HR 2.20, 95% CI p-interaction = 0.045).
conclusionsThe benefits of earlier ablation in reducing AF recurrence might not equate to improvements in post-ablation cardiovascular prognosis. Timely treatment combining AADs and ablation may provide additional cardiovascular benefits.
trial registrationClinicalTrials.gov Identifier: NCT00911508.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.